Cardinal Plans Geographic, Services Expansion In China As Massive Consolidation Steams Ahead
This article was originally published in PharmAsia News
Cardinal is entering new fields, including direct-to-patient distribution, as it tries to differentiate itself from local Chinese distributors.
You may also be interested in...
Cardinal Health's Acquisition Of Zuellig Pharma Signal Of China's Intent To Allow More Foreign Investment?
A regulatory framework that encourages physicians to conduct experimental cell and gene therapies have propelled China to become a major developer of such promising cancer-treating tools, but insiders say three are a plethora issues at stake.